Physician profile
John Paul Dehler
NPI 1982705166
$3,362.30
in general payments reported to CMS, 2019-2025
19 companies · $1,692 in 2025
The $1,692 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $215 · 2022: $34.83 · 2023: $159 · 2024: $1,261 · 2025: $1,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,112.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $723.06 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $687.93 | 2021-2025 | |
| Novo Nordisk INC | $475.65 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Phathom Pharmaceuticals, INC. | $359.88 | 2024-2025 | Voquezna |
| Pfizer INC. | $224.47 | 2021-2025 | |
| Lilly USA, LLC | $208.86 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $173.68 | 2023-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $91.10 | 2021-2025 | Trelegy Ellipta |
| Horizon Therapeutics Plc | $77.73 | 2021 | |
| Seqirus USA INC | $77.71 | 2024-2025 | Fluad, Flucelvax |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.70 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.88 | 2021-2025 | Jardiance |
| Exact Sciences Corporation | $40.13 | 2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $23.70 | 2025 | Symbravo |
| Orthogenrx INC. | $23.13 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $20.63 | 2024 | Yupelri |
| Dermavant Sciences, INC. | $19.88 | 2024 | Vtama |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.76 | 2025 | Caplyta |
| Currax Pharmaceuticals LLC | $13.42 | 2024 | Onzetra Xsail, Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dehler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.